Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 8 Best Genomics Stocks to Buy According to Analysts.
On May 28, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) said partner GSK reported pivotal Phase 3 data for bepirovirsen
The corporation disclosed a 19% functional cure rate as compared to 0% on standard care, while reaching 26% in patients with lower viral activity. The trials, B-Well 1 and B-Well 2, met primary endpoints. Ionis stated that 233 of 1,220 treated patients achieved a functional cure versus none in the placebo group.
The company also reported 49% of treated patients reached surface antigen levels ≤100 IU/mL one year post-treatment, while 23% achieved sustained viral suppression at week 72. Ionis mentioned adverse events included injection site reactions and temporary liver enzyme hikes. Chief Executive Officer Brett P.